Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada

BMC Public Health

Table 2 Interrupted time series of average daily diazepam equivalence differences per patient in medically authorized cannabis users (n = 9690) vs controls (n = 9690)

Variable	Daily diazepam equivalence difference (95% CI) ^a
Pre-incentive trend ^c	− 0.02 (− 0.05 to 0.02)
Level change after medical cannabis authorization ^d	−0.08 (− 0.41 to 0.24)
Trend change after medical cannabis authorization ^e	0.04 (− 0.01 to 0.09)
Overall absolute effect after medical cannabis authorization ^f	0.32 (−0.23 to 0.87)

^aAll reported values indicate the average difference in average daily diazepam equivalence per patient in those who received a medical cannabis authorization compared to controls
^cRate of change in the outcome over time prior to medical cannabis authorization
^dImmediate change in outcome following medical cannabis authorization
^eMonth to month change in average daily diazepam equivalence or slope after medical cannabis authorization, relative to the pre-incentive difference in trend
^fThe overall absolute effect after medical cannabis authorization is the absolute difference in the average daily diazepam equivalence over the 12 months pre- and 12 months post-medical cannabis authorization period, compared to the counterfactual difference in trends had medical cannabis authorization not occurred (i.e. pre-incentive difference in trends projected forward)

ISSN: 1471-2458